Selenium-Containing Heterocycles From Isoselenocyanates: Synthesis of 1,3-Selenazolidine and Perhydro-1,3-selenazine Derivatives by Sommen, Geoffroy L et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2005
Selenium-Containing Heterocycles From Isoselenocyanates: Synthesis of
1,3-Selenazolidine and Perhydro-1,3-selenazine Derivatives
Sommen, Geoffroy L; Linden, Anthony; Heimgartner, Heinz
Abstract: Treatment of ￿-halo alkylamines 9 and 10 with aryl and alkyl isoselenocyanates 6a–g in the pres-
ence of triethylamine in dichloromethane gave the corresponding 1,3-selenazolidines 11a–g and perhydro-
1,3-selenazines 12a–g, respectively, in good to excellent yields. Chemical and spectroscopic evidence for
the structures of all new compounds are presented, and in selected examples the molecular structures
have been established by X-ray crystallography. The analogous reactions with isothiocyanates have been
used for the preparation of 1,3-thiazolidines and perhydro-1,3-thiazines.
DOI: 10.1002/ejoc.200500090
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-65013
Originally published at:
Sommen, Geoffroy L; Linden, Anthony; Heimgartner, Heinz (2005). Selenium-Containing Heterocycles
From Isoselenocyanates: Synthesis of 1,3-Selenazolidine and Perhydro-1,3-selenazine Derivatives. Euro-
pean Journal of Organic Chemistry, (14):3128-3137. DOI: 10.1002/ejoc.200500090
FULL PAPER
Selenium-Containing Heterocycles From Isoselenocyanates: Synthesis of
1,3-Selenazolidine and Perhydro-1,3-selenazine Derivatives
Geoffroy L. Sommen,[a,b] Anthony Linden,[a] and Heinz Heimgartner*[a]
Keywords: Cyclizations / Isoselenocyanates / Selenium heterocycles / Sulfur heterocycles / X-ray crystallography
Treatment of ω-halo alkylamines 9 and 10 with aryl and alkyl
isoselenocyanates 6a–g in the presence of triethylamine in
dichloromethane gave the corresponding 1,3-selenazolidines
11a–g and perhydro-1,3-selenazines 12a–g, respectively, in
good to excellent yields. Chemical and spectroscopic evi-
dence for the structures of all new compounds are presented,
Introduction
The chemistry of organoselenium compounds has at-
tracted much attention, not only because of strong interest
in these compounds as synthetic tools[1–8] but also as a re-
sult of their unique biological[9,10] and medicinal activi-
ties.[11–19] Hatfield[20] demonstrated the wide importance of
organoselenium compounds in human health, especially in
cancer chemoprevention,[21] in food,[22–24] and in
plants.[25,26] Although syntheses of thiazines[27] and ox-
azines[28,29] are well known, those of the corresponding selen-
azines have been limited, owing to difficulties in the prepa-
ration of the selenium-containing starting materials. Like
many other syntheses of selenium-containing heterocycles,
they involve the use of toxic selenium reagents, which are
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and in selected examples the molecular structures have been
established by X-ray crystallography. The analogous reac-
tions with isothiocyanates have been used for the prepara-
tion of 1,3-thiazolidines and perhydro-1,3-thiazines.
(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim,
Germany, 2005)
often difficult to handle. Isoselenocyanates[30–32] are very
useful starting materials in heterocyclic chemistry[33] be-
cause they are easy to prepare[34] and can be stored.
Selenazines have attracted much attention not only in
medicinal fields (antibacterial effects against Escherichia
coli and Staphylococcus aureus,[35] inhibitory effect on the
proliferation of human HT-1080 fibrosarcoma cells,[36] pro-
tein kinase inhibition,[37] and as antitumor agents[38]), but
also as dyes.[39,40] Nevertheless, the preparation of this ring
system is not well described in the literature, and only re-
cently have some reports and reviews on the synthesis and
applications of selenazines been published.[39,40] Similarly,
selenazoles have attracted attention in the chemistry of dye-
stuffs,[41,42] as well as in medicine (antiinfective,[36] antivi-
ral,[43] and antitumor agents[44]).
To the best of our knowledge, only a few papers describe
the preparation of nonfused selenazoles from an isoseleno-
cyanate[45–48] and, surprisingly, only one selenazole deriva-
tive prepared from a primary amine has been described.[49]
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We have recently shown that aryl isoselenocyanates 1 are
convenient precursors for the introduction of selenium into
five- and six-membered selenaheterocycles of types 3[50] and
5,[51] respectively (Scheme 1). The aromatic starting materi-
als 2 and 4 for these reactions each bore a primary amino
group and a halogen atom. The formation of 1H-1,3,6-tri-
azaaceanthrylene derivatives 5 occurred on heating of 1 and
4 in boiling pyridine without any additional reagents. Simi-
larly, 2-arylamino selenazolo[5,4-b]pyridines 3 were pre-
pared from 1 and 2 in propan-2-ol at reflux. In the latter
case, however, the product was obtained as the hydrochlo-
ride, which was very stable and gave the free amine deriva-
tive only with difficulty.
As a continuation of our studies in isoselenocyanate
chemistry[50–57] we investigated the synthesis of five- and
six-membered Se/N-heterocycles: 1,3-selenazoles and 1,3-
Scheme 2.
Table 1. Preparation of 1,3-selenazolidines 9 and 1,3-selenazines 10 from isoselenocyanates 6.
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selenazines. In this paper we report on reactions of aryl and
alkyl isoselenocyanates 1 with the ω-halogeno alkylamines
9 and 10.
Results and Discussion
The halogenoamine (HX salt, one equiv.) was added to
a stirred solution of the appropriate freshly prepared isose-
lenocyanate 6 in dry dichloromethane, followed by
two equiv. of triethylamine. The isoselenocyanates 6 used
were easily prepared from the corresponding N-arylforma-
mides by treatment with phosgene and elemental selenium,
by the procedure published by Barton et al.[34a] Stirring of
the solution of 6 and 7 or 8 at room temperature for 4 h
(except for cyclohexyl isoselenocyanate: 12 h) resulted in the
formation of the selenium-containing heterocycles 9 and 10,
respectively, isolated in 39–96% yields (Scheme 2, Table 1).
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As shown in Table 1, the yields of the six-membered het-
erocycles 10 were, in general, higher than those of the corre-
sponding five-membered heterocycles. Quite large differ-
ences were observed between 9f and 10f and between 9g
and 10g, the two cases in which the steric hindrance be-
tween the residue at the imine N-atom and the heterocycle
is the greatest.
We propose the following reaction mechanism for the
formation of 9 and 10: addition of the primary amino
group to 6 produces a selenourea derivative A, which un-
dergoes a cyclization step to give the heterocyclic product.
In this one-pot, multi-step procedure, the cascade needs two
equivalents of base. Triethylamine was chosen for its soft-
ness and for the ease of its elimination by washing the reac-
tion mixture with water.
The structures of the selenazolidin-2-imines 9 were as-
signed on the basis of their spectroscopic data and elemen-
tal analyses. The crystal structures of 9a and 9d were also
established by X-ray crystallography (Figure 1 and Fig-
ure 2). The products are 1,3-selenazolidines, each with an
exocyclic C,N double bond.
Figure 1. ORTEP plot[58] of the molecular structure of the two sym-
metry-independent molecules of 9a (arbitrary numbering of atoms;
displacement ellipsoids with 50% probability).
In the case of 9a there are two symmetry-independent
molecules, in which the orientations of the phenyl rings are
quite different, in the asymmetric unit. The five-membered
ring in molecule A has an envelope conformation with C(4)
as the envelope flap. The heterocyclic ring in molecule B
also has an envelope conformation, but is more distorted
from ideal geometry than the ring in molecule A and a dif-
ferent ring atom – C(25) – forms the envelope flap. Al-
though the compound is achiral, it crystallized in a noncen-
trosymmetric polar space group. The absolute structure was
determined independently by the diffraction experiment.
The NH group in molecule A forms an intermolecular hy-
drogen bond with the imine N-atom of a neighboring mole-
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Figure 2. ORTEP plot[58] of the molecular structure of the two con-
formations of 9d (arbitrary numbering of atoms; displacement el-
lipsoids with 50% probability).
cule B. In turn, molecule B has the same mode of hydrogen
bonding with the original molecule A, the hydrogen bonds
thereby linking one molecule A and one molecule B into a
dimeric unit by forming a loop with a binary graph set mo-
tif[59] of R22(8).
In the case of 9d, the methylene groups in the heterocy-
clic ring are disordered over two conformations, with the
major conformation occurring in approximately 70% of the
molecules. The heterocyclic ring in the major conformation
has a slightly distorted half-chair conformation twisted on
C(4a)–C(5a), with the distortion being in the direction of
an envelope with C(5a) as the envelope flap. The minor con-
formation lies closer to that of an envelope with C(5b) as
the envelope flap. The disorder is essentially the result of
the envelope flap lying on opposite sides of the heterocyclic
ring plane. Similarly to 9a, the NH group forms an inter-
molecular hydrogen bond with the imine N-atom of a
neighboring molecule. In turn, the acceptor molecule do-
nates the same type of hydrogen bond back to the original
molecule, thereby forming centrosymmetric dimeric units.
The hydrogen bonding motif in these dimers is also R22(8).
The structures of the selenazan-2-imines 10 were simi-
larly deduced from their elemental analyses and spectro-
scopic data. The molecular structures of 10a and 10c were
verified by single-crystal X-ray analyses (Figure 3 and Fig-
ure 4).
There are two symmetry-independent molecules in the
asymmetric unit of 10a. The conformations of the indepen-
dent molecules differ primarily in the puckering of the het-
erocyclic ring. In molecule A the ring has a screw-boat con-
formation, while in molecule B the ring has an envelope
conformation with C(25) as the envelope flap. The NH
group in molecule A forms an intermolecular hydrogen
bond with the imine N-atom of a neighboring molecule A.
In turn, the acceptor molecule donates the same type of
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Figure 3. ORTEP plot[58] of the molecular structure of the two sym-
metry-independent molecules of 10a (arbitrary numbering of
atoms; displacement ellipsoids with 50% probability).
Figure 4. ORTEP plot[58] of the molecular structure of 10c (arbi-
trary numbering of atoms; displacement ellipsoids with 50% prob-
ability).
hydrogen bond back to the original molecule, thereby form-
ing centrosymmetric dimeric units composed entirely of A
molecules. The hydrogen bonding motif[59] in these dimers
is again R22(8). The same pattern of intermolecular hydro-
gen bonds links the B molecules into dimeric units.
In the case of 10c, the heterocyclic ring has a distorted
envelope conformation with C(5) as the envelope flap. The
distortion is in the direction of a half-chair twisted on C(4)–
C(5). Intermolecular hydrogen bonds between the NH
group and the imine N-atom of a neighboring molecule link
the molecules into centrosymmetric dimeric units, analo-
gously to 10a.
For the preparation of 9 and 10, the organic base trieth-
ylamine was chosen to avoid secondary reactions. When
stronger bases such as sodium hydroxide were used for the
reactions of 6 with 7 and 8, the formation of compounds
11 and 12, respectively, was observed (Scheme 3). The 2:1
adduct 11 was obtained in 81% yield through a subsequent
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reaction between another equivalent of 6a and the N-atom
of the selenazolidine ring of 9a. The homologous com-
pound 12 was obtained similarly via the intermediate selen-
azane 10a. In fact, the formation of product 11 was our
first result in this study. We then focused our attention on
the optimization of the synthesis of the initially formed se-
lenazole ring by varying the solvent and the base. The opti-
mal conditions proved to be a 1:1 mixture of 6 and 7 or 8
and two equivalents of triethylamine in dichloromethane at
room temperature for ca. 4 h. The first equivalent of the
base is needed to generate the free amine in situ, and the
second to capture HX formed during the cyclization step.
The triethylammonium salt was removed by washing the
reaction mixture with water.
Scheme 3.
Crystallization of 11 from dichloromethane gave suitable
crystals for the structure to be established by X-ray crystal-
lography (Figure 5). Although the compound is achiral, it
crystallized in a polar space group and the absolute struc-
ture was determined by the diffraction experiment. The
five-membered heterocycle has an envelope conformation
with C(5) as the envelope flap. The adjacent atoms N(6),
C(7), C(13), and N(14) deviate only slightly from the plane
defined by Se(1), C(2), N(3), and C(4), but the phenyl resi-
dues at N(6) and N(14) are twisted out of this plane by ca.
62° and 49°, respectively. The NH group forms an intramol-
ecular hydrogen bond with the imine N-atom and thereby
creates a six-membered loop with a graph set motif of S(6).
The above syntheses of 1,3-selenazolidines and 1,3-selen-
azanes are part of our research program started some years
ago with the aim of synthesizing selenium-containing het-
erocycles. Notwithstanding, we also carried out a biblio-
graphic search on the corresponding sulfur analogues: 1,3-
thiazolidines and 1,3-thiazines. Surprisingly, we found no
similar procedure for the preparation of these heterocycles
from isothiocyanates and 7 or 8, and so we decided to inves-
tigate these reactions too. Under analogous conditions we
obtained the 1,3-thiazolidines 14a and 14b and the 1,3-thi-
azanes 15a and 15b in almost quantitative yields (Scheme 4,
Table 2).
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Figure 5. ORTEP plot[58] of the molecular structure of 11 (arbitrary
numbering of atoms; displacement ellipsoids with 50% prob-
ability).
Scheme 4.
Table 2. Preparation of 1,3-thiazolidines 14 and 1,3-thiazines 15 from isothiocyanates 13.
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Conclusions
In summary, we have shown that 1,3-selenazolidin-2-
imines 9 and 1,3-selenazin-2-imines 10 can easily be synthe-
sized with excellent yields in one-pot reactions by starting
from aryl and alkyl isoselenocyanates and ω-haloalkyl-
amines in basic media. The analogous reaction with isothio-
cyanates opens a novel and efficient route to the corre-
sponding sulfur heterocycles.
Experimental Section
General Remarks: TLC: silica gel 60 F254 plates (0.25 mm; Merck).
Column chromatography (CC): silica gel 60 (0.040–0.063 mm;
Merck). Melting point (M.p.): Büchi B-540 apparatus, in capillary;
uncorrected. IR spectra: KBr (cm–1).1H NMR (300 MHz) and 13C
NMR (75 MHz) spectra: Bruker ARX 300 instrument, in CDCl3
unless otherwise specified; chemical shifts in ppm, coupling con-
stants (J) in Hz. EI-MS and CI-MS: Finnigan SSQ-700 or MAT-
90 instruments. EI mode: 70 eV; CI mode: NH3 as carrier gas.
Starting Materials: 2-Bromoethylamine (HBr salt) and 3-chloro-
propylamine (HCl salt) are commercially available (Fluka). Isose-
lenocyanates were prepared by Barton’s procedure, by starting from
formamides.[34a] Formanilide and N-cyclohexylformamide are com-
mercially available (Fluka and Aldrich), N-(4-chlorophenyl)-, N-(4-
bromophenyl)-, and N-(4-methoxyphenyl)formamide were pre-
pared from the corresponding anilines and 95% formic acid by a
slightly modified literature protocol:[60] the solution was heated to
reflux for 30 min and the solvents were evaporated to dryness in
vacuo. The residue was dissolved in Et2O and washed with dilute
AcOH (5%), H2O, and aqueous NaHCO3 (5% aq.). The aqueous
layer was extracted with Et2O, and the combined organic extracts
were dried over MgSO4 and evaporated under reduced pressure.
The crude products were purified by recrystallization from mixtures
of EtOH and H2O.
General Procedure for the Preparation of 1,3-Selenzolidines 9a–g
and 1,3-Selenazanes 10a–g: A 25 mL round-bottomed flask fitted
with a magnetic stirrer and condenser was charged with a solution
of the appropriate isoselenocyanate (1.0 mmol) in CH2Cl2 (20 mL).
2-Bromoethylamine hydrobromide or 3-chloropropylamine hydro-
chloride (1.0 mmol) was added, followed by Et3N (0.28 mL,
2.0 mmol), and the mixture was stirred for 4 h at room temperature
(except for cyclohexyl isoselenocyanate: 12 h). The mixture was
washed with H2O (3×10 mL) and the solvents were evaporated to
dryness under reduced pressure. The crude product was purified by
column chromatography on silica gel with hexane/AcOEt (1:0 to
1:1).
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Phenyl(1,3-selenazolidin-2-yliden)amine (9a): Yield: 146 mg (65%).
Colorless crystals. M.p. 167–169 °C (CH2Cl2). 1H NMR: δ = 3.31
(t, J = 6.8 Hz, 2 H), 3.74 (t, J = 6.8 Hz, 2 H), 6.15 (br s, NH), 7.04–
7.09 (m, 3×arom. H), 7.28 (t, J = 6.2 Hz, 2×arom. H) ppm. 13C
NMR: δ = 25.8 (CH2), 49.5 (CH2), 121.1 (2×arom. CH), 123.5
(1×arom. CH), 129.0 (2×arom. CH), 149.7 (1×arom. C), 160.1
(C(2)) ppm. IR: ν˜ = 1630 (s), 1584 (s), 1488 (m), 1354 (w), 1291
(w), 1253 (w), 1194 (m), 1163 (w), 1074 (m), 943 (w), 900 (w), 836
(m), 769 (m), 700 (m) cm–1. CI-MS: 225 (49) [M(78Se) + H]+, 227
(100) [M(80Se) + H]+. C9H10N2Se (225.15): C 48.01, H 4.48, N
12.44; found: C 48.17, H 4.52, N 12.43.
Suitable crystals for the X-ray crystal structure determination were
grown from CH2Cl2 by slow evaporation of the solvent.
(4-Bromophenyl)(1,3-selenazolidin-2-yliden)amine (9b): Yield:
292 mg (96%). Yellowish crystals. M.p. 160–162 °C (CH2Cl2). 1H
NMR: δ = 3.33 (t, J = 6.8 Hz, CH2), 3.70 (t, J = 6.8 Hz, CH2),
6.90 (br s, NH), 6.90, 7.38 (AABB, 4×arom. H) ppm. 13C NMR:
δ = 25.4 (CH2), 48.5 (CH2), 116.4 (1×arom. C), 122.9 (2×arom.
CH), 132.0 (2×arom. CH), 149.4 (1×arom. C), 160.8 (C(2)) ppm.
IR: ν˜ = 1625 (s, br), 1575 (m), 1486 (m), 1458 (w), 1254 (w), 1197
(m), 1100 (w), 1071 (m), 841 (w) cm–1. CI-MS: 303 (46) [M(78Se,
79Br) + H]+, 304 (15), 305 (100) [M(80Se, 79Br) + H]+, 306 (11), 307
(78) [M(80Se, 81Br) + H]+. C9H9N2SeBr (304.05): C 35.55, H 3.31,
N 9.21; found: C 35.65, H 3.16, N 9.05.
(4-Chlorophenyl)(1,3-selenazolidin-2-yliden)amine (9c): Yield:
220 mg (85%). Yellowish crystals. M.p. 162–164 °C (CH2Cl2). 1H
NMR: δ = 3.33 (t, J = 6.8 Hz, CH2), 3.74 (t, J = 6.8 Hz, CH2),
5.15 (br s, NH), 6.95, 7.25 (AABB, 4×arom. H) ppm. 13C NMR:
δ = 25.5 (CH2), 48.6 (CH2), 122.5 (2×arom. CH), 128.9 (1×arom.
C), 129.0 (2×arom. CH), 148.5 (1×arom. C), 161.0 (C(2)) ppm.
IR: ν˜ = 1625 (s, br), 1579 (m), 1488 (m), 1460 (w), 1354 (w), 1298
(w), 1254 (w), 1197 (m), 1073 (w), 833 (w) cm–1. CI-MS: 259 (47)
[M(78Se, 35Cl) + H]+, 260 (10), 261 (100) [M(80Se, 35Cl) + H]+, 263
(42) [M(80Se, 37Cl) + H]+. C9H9N2SeCl (259.59): C 41.64, H 3.49,
N 10.79; found: C 41.55, H 3.75, N 10.63.
(4-Methoxyphenyl)(1,3-selenazolidin-2-yliden)amine (9d): Yield:
166 mg (65%). Colorless crystals. M.p. 133–135 °C (CH2Cl2). 1H
NMR: δ = 3.27 (t, J = 6.8 Hz, CH2), 3.71 (t, J = 6.8 Hz, CH2), 3.78
(s, Me), 6.34 (br s, NH), 6.82, 6.96 (AABB, 4×arom. H) ppm. 13C
NMR: δ = 25.6 (CH2), 49.3 (CH2), 55.3 (Me), 114.2 (2×arom.
CH), 122.4 (2×arom. CH), 143.6 (1×arom. C), 156.0 (1×arom.
C), 160.6 (C(2)) ppm. IR: ν˜ = 1631 (s, br), 1504 (s), 1356 (w), 1293
(m), 1243 (s), 1192 (s), 1099 (w), 1068 (m), 1035 (m), 944 (w), 825
(m), 764 (m) cm–1. CI-MS: 255 (51) [M(78Se) + H]+, 257 (100)
[M(80Se) + H]+. C10H12N2OSe (255.18): C 47.07, H 4.74, N 10.98;
found: C 46.73, H 4.73, N 10.77.
(4-Methylphenyl)(1,3-selenazolidin-2-yliden)amine (9e): Yield:
170 mg (71%). Colorless crystals. M.p. 142–144 °C (CH2Cl2). 1H
NMR: δ = 2.31 (s, Me), 3.32 (t, J = 6.8 Hz, CH2), 3.75 (t, J =
6.8 Hz, CH2), 6.02 (br s, NH), 6.95, 7.09 (AABB, 4×arom.
H) ppm. 13C NMR: δ = 20.8 (Me), 25.9 (CH2), 49.8 (CH2), 121.0
(2×arom. CH), 129.6 (2×arom. CH), 133.1 (1×arom. C), 146.9
(1×arom. C), 159.9 (C(2)) ppm. IR: ν˜ = 1630 (s), 1599 (s), 1505
(m), 1461 (w), 1351 (w), 1290 (w), 1252 (w), 1194 (m), 1172 (w),
1108 (w), 1071 (w), 820 (m), 772 (w) cm–1. CI-MS: 239 (48)
[M(78Se) + H]+, 241 (100) [M(80Se) + H]+. C10H12N2Se (239.18): C
50.22, H 5.06, N 11.71; found: C 50.52, H 5.23, N 11.76.
(2,6-Dimethylphenyl)(1,3-selenazolidin-2-yliden)amine (9f): Yield:
180 mg (71%). Colorless crystals. M.p. 142–144 °C (CH2Cl2). 1H
NMR: δ = 2.18 (s, 2×Me), 3.25 (t, J = 6.8 Hz, CH2), 3.63 (t, J =
6.8 Hz, CH2), 6.15 (br s, NH), 6.88–6.98 (m, 1×arom. H), 7.38 (d,
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J = 8.7 Hz, 2×arom. H) ppm. 13C NMR: δ = 18.0 (2×Me), 24.9
(CH2), 48.2 (CH2), 123.7 (2×arom. C), 127.9 (2×arom. CH), 130.5
(2×arom. C), 149.0 (1×arom. C), 161.4 (C(2)) ppm. IR: ν˜ = 1636
(s, br), 1588 (m), 1472 (m), 1431 (w), 1352 (w), 1286 (w), 1258 (w),
1191 (w), 1091 (w), 834 (w), 766 (m) cm–1. CI-MS: 253 (56)
[M(78Se) + H]+, 255 (100) [M(80Se) + H]+. C11H14N2Se (253.20): C
52.18, H 5.57, N 11.06; found: C 52.32, H 5.33, N 11.36.
(Cyclohexyl)(1,3-selenazolidin-2-yliden)amine (9g): Yield: 90 mg
(39%). Yellowish crystals. M.p. 173–175 °C (CH2Cl2) (ref.[74] 170°).
1H NMR: δ = 1.29–1.54 (m, 4 H), 1.56–1.83 (m, 4 H), 2.01–2.07
(m, 2 H), 3.18 (t, J = 6.8, Hz CH2), 4.42–4.50 (m, 1 H), 5.08 (t, J
= 6.8 Hz, CH2), 5.85 (br s, NH) ppm. 13C NMR: δ = 19.2 (CH2),
24.1 (2×CH2), 25.4 (CH2), 33.5 (2×CH2), 56.6 (CH2), 58.9 (CH),
151.1 (C(2)) ppm. IR: ν˜ = 1726 (w), 1668 (m), 1567 (s, br), 1449
(m), 1410 (w), 1362 (w), 1307 (w), 1277 (w), 1223 (w), 1159 (m),
1137 (w), 1073 (w), 1025 (w), 975 (w), 890 (w), 854 (m), 794 (w),
736 (w) cm–1. CI-MS: 231 (48) [M(78Se) + H]+, 233 (100) [M(80Se)
+ H]+. C9H16N2Se (231.20): C 46.76, H 6.98, N 12.12; found: C
46.66, H 6.46, N 11.85.
Phenyl(1,3-selenazan-2-yliden)amine (10a): Yield: 210 mg (88%).
Yellowish crystals. M.p. 121–123 °C (CH2Cl2). 1H NMR: δ = 2.04–
2.11 (m, CH2), 3.01 (t, J = 6.8 Hz, CH2), 3.41 (t, J = 6.8 Hz, CH2),
5.74 (br s, 1 H), 7.02–7.07 (m, 3×arom. H), 7.23–7.29 (m, 2×arom.
H) ppm. 13C NMR: 20.9 (CH2), 23.9 (CH2), 44.7 (CH2), 122.3
(2×arom. CH), 123.5 (1×arom. CH), 128.9 (2×arom. CH), 146.5
(1×arom. C), 149.6 (C(2)) ppm. IR: ν˜ = 1630 (s), 1584 (s), 1488
(m), 1354 (w), 1291 (w), 1253 (w), 1194 (m), 1163 (w), 1074 (m),
943 (w), 900 (w), 836 (m), 769 (m), 700 (m) cm–1. CI-MS: 239 (50)
[M(78Se) + H]+, 241 (100) [M(80Se) + H]+. C10H12N2Se (239.18): C
50.22, H 6.06, N 11.71; found: C 50.66, H 5.23, N 11.76.
Suitable crystals for the X-ray crystal-structure determination were
grown from CH2Cl2 by slow evaporation of the solvent.
(4-Bromophenyl)(1,3-selenazan-2-yliden)amine (10b): Yield: 299 mg
(94%). M.p. 141–143 °C (CH2Cl2). 1H NMR: δ = 2.05–2.13 (m,
CH2), 3.00 (t, J = 6.8 Hz, CH2), 3.39 (t, J = 6.8 Hz, CH2), 6.02
(br s, NH), 6.89, 7.35 (AABB, 4×arom. H) ppm. 13C NMR: δ
= 20.8 (CH2), 24.0 (CH2), 44.3 (CH2), 115.9 (1×arom. C), 123.9
(2×arom. CH), 131.8 (2×arom. CH), 146.5 (1×arom. C), 149.6
(C(2)) ppm. IR: ν˜ = 1621 (s, br), 1575 (s), 1488 (s), 1463 (m), 1427
(w), 1385 (w), 1349 (w), 1319 (w), 1276 (w), 1265 (w), 1203 (s),
1159 (s), 1098 (m), 1066 (w), 1003 (m), 944 (w), 869 (w), 833 (m),
754 (w) cm–1. CI-MS: 317 (100) [M(78Se, 79Br) + H]+, 318 (17), 319
(100) [M(80Se, 79Br) + H]+, 321 (77) [M(80Se, 81Br) + H]+.
C10H11N2SeBr (318.07): C 37.76, H 3.49, N 8.81; found: C 37.84,
H 3.60, N 8.81.
(4-Chlorophenyl)(1,3-selenazan-2-yliden)amine (10c): Yield: 216 mg
(79%). Yellowish crystals. M.p. 134–136 °C (CH2Cl2). 1H NMR: δ
= 2.08–2.17 (m, CH2), 3.02 (t, J = 6.8 Hz, CH2), 3.42 (t, J = 6.8 Hz,
CH2), 5.20 (br s, NH), 6.96, 7.23 (AABB, 4×arom. H) ppm. 13C
NMR: δ = 20.8 (CH2), 24.0 (CH2), 44.3 (CH2), 123.5 (2×arom.
CH), 128.2 (1×arom. C), 128.8 (2×arom. CH), 146.2 (1×arom.
C), 149.8 (C(2)) ppm. IR: ν˜ = 1625 (s), 1583 (m), 1489 (s), 1463
(m), 1428 (w), 1384 (w), 1351 (w), 1320 (w), 1269 (w), 1207 (s),
1159 (s), 1103 (m), 1086 (m), 1010 (m), 870 (m), 837 (m), 765
(w) cm–1. CI-MS: 273 (50) [M(78Se, 35Cl) + H]+, 274 (12), 275 (100)
[M(80Se, 35Cl) + H]+, 277 (44) [M(80Se, 37Cl) + H]+. C10H11N2SeCl
(273.62): C 43.90, H 4.05, N 10.24; found: C 44.13, H 4.24, N
10.17.
Suitable crystals for the X-ray crystal structure determination were
grown from CH2Cl2 by slow evaporation of the solvent.
(4-Methoxyphenyl)(1,3-selenazan-2-yliden)amine (10d): Yield:
247 mg (92%). Yellowish crystals. M.p. 113–115 °C (CH2Cl2). 1H
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NMR: δ = 2.04–2.12 (m, CH2), 2.98 (t, J = 6.8 Hz, CH2), 3.39 (t,
J = 6.8 Hz, CH2), 3.78 (s, Me), 6.12 (br s, NH), 6.81, 6.95 (AABB,
4×arom. H) ppm. 13C NMR: δ = 20.7 (CH2), 24.0 (CH2), 44.5
(CH2), 55.3 (Me), 114.0 (2×arom. CH), 123.6 (2×arom. CH),
139.9 (1×arom. C), 149.9 (1×arom. C), 156.0 (C(2)) ppm. IR: ν˜ =
1632 (s, br), 1504 (s), 1459 (m), 1439 (w), 1346 (m), 1316 (w), 1235
(s), 1206 (s), 1162 (m), 1099 (m), 1033 (s), 1015 (m), 949 (w), 871
(m), 839 (m), 758 (m), 726 (w) cm–1. CI-MS: 269 (51) [M(78Se) +
H]+, 271 (100) [M(80Se) + H]+. C11H14N2OSe (269.21): C 49.08, H
5.24, N 10.41; found: C 49.24, H 5.41, N 10.35.
(4-Methylphenyl)(1,3-selenazan-2-yliden)amine (10e): Yield: 220 mg
(87%). Yellowish crystals. M.p. 107–109 °C (CH2Cl2). 1H NMR: δ
= 2.03–2.11 (m, CH2), 2.30 (s, Me), 2.99 (t, J = 6.8 Hz, CH2), 3.40
(t, J = 6.8 Hz, CH2), 5.65 (br s, NH), 6.93, 7.07 (AABB, 4×arom.
H) ppm. 13C NMR: δ = 20.8 (Me, CH2), 23.8 (CH2), 44.6 (CH2),
122.3 (2×arom. CH), 129.4 (2×arom. CH), 133.0 (1×arom. C),
143.6 (1×arom. C), 149.9 (C(2)) ppm. IR: ν˜ = 1622 (s), 1602 (s),
1506 (s), 1470 (m), 1427 (w), 1377 (w), 1349 (m), 1313 (m), 1265
(m), 1212 (m), 1161 (m), 1101 (w), 1011 (w), 945 (w), 873 (m), 822
(m), 761 (w), 717 (w) cm–1. CI-MS: 253 (53) [M(78Se) + H]+, 255
(100) [M(80Se) + H]+. C11H14N2Se (253.20): C 52.18, H 5.57, N
11.06; found: C 52.43, H 5.79, N 11.33.
(2,6-Dimethylphenyl)(1,3-selenazan-2-yliden)amine (10f): Yield:
235 mg (88%). Yellowish crystals. M.p. 133–135 °C (CH2Cl2). 1H
NMR: δ = 2.04–2.12 (m, CH2), 2.18 (s, 2×Me), 2.91 (t, J = 6.8 Hz,
CH2), 3.30 (t, J = 6.8 Hz, CH2), 6.02 (br s, NH), 6.87–7.00 (m,
3×arom. H) ppm. 13C NMR: δ = 18.1 (2×Me), 20.2 (CH2), 24.7
(CH2), 43.8 (CH2), 123.3 (1×arom. CH), 127.7 (2×arom. CH),
131.1 (2×arom. C), 145.4 (1×arom. C), 149.5 (C(2)) ppm. IR: ν˜ =
1615 (s), 1584 (s), 1506 (w), 1480 (s), 1432 (m), 1383 (w), 1351 (w),
1313 (s), 1265 (s), 1252 (m), 1202 (s), 1163 (s), 1105 (m), 1090 (s),
1004 (m), 872 (m), 828 (m), 778 (m), 764 (s), 703 (w) cm–1. CI-MS:
267 (54) [M(78Se) + H]+ 269 (100) [M(80Se) + H]+. C12H16N2Se
(267.23): C 53.93, H 6.04, N 10.48; found: C 54.04, H 6.30, N
10.23.
Cyclohexyl(1,3-selenazan-2-yliden)amine (10g): Yield: 225 mg
(92%). Colorless crystals. M.p. 113–115 °C (CH2Cl2). 1H NMR: δ
= 1.08–1.29 (m, 4 H), 1.32–1.41 (m, 2 H), 1.66–1.81 (m, 4 H), 1.94–
2.01 (m, 2 H), 3.10 (t, J = 6.8 Hz, CH2), 3.50 (t, J = 6.8 Hz, CH2),
3.58–3.67 (m, 1 H), 4.45 (br s, NH) ppm. 13C NMR: δ = 20.9 (CH2),
21.3 (CH2), 24.7 (2×CH2), 25.7 (CH2), 33.3 (2×CH2), 47.7 (CH2),
51.1 (CH), 145.6 (C(2)) ppm. IR: ν˜ = 1609 (s, br), 1525 (s), 1448
(m), 1374 (m), 1339 (m), 1295 (w), 1282 (w), 1258 (w), 1240 (m),
1169 (w), 1150 (m), 1099 (m), 1062 (w), 1002 (w), 972 (m), 925 (w),
889 (w), 859 (w), 826 (w), 730 (w) cm–1. CI-MS: 245 (48) [M(78Se)
+ H]+, 247 (100) [M(80Se) + H]+. C10H18N2Se (245.22): C 48.98, H
7.40, N 11.42; found: C 49.16, H 7.23, N 11.02.
General Procedure for the Preparation of 11 and 12: A 25 mL round-
bottomed flask fitted with a magnetic stirrer and condenser was
charged with a solution of the phenyl isoselenocyanate (1.0 mmol)
in THF (20 mL). Bromoethylamine hydrobromide (for 11) or 3-
chloropropylamine hydrochloride (for 12) (0.5 equiv.) was added,
followed by aqueous NaOH (1 m, 2 equiv.), and the mixture was
stirred for 6 h at room temperature. The mixture was then diluted
with CH2Cl2 (50 mL), washed with H2O (3×15 mL), and dried
over MgSO4, and the solvents were evaporated to dryness under
reduced pressure. The crude product was purified by column
chromatography on silica gel with hexane/AcOEt (3:1 to 1:3).
2-(Phenylimino)-1,3-selenazolidine-3-carboselenoic Anilide (11):
Yield: 173 mg (81%). Yellowish crystals. M.p. 119–121 °C
(CH2Cl2). 1H NMR: 3.21 δ = (t, J = 6.8 Hz, CH2), 5.29 (t, J =
6.8 Hz, CH2), 6.96 (d, J = 8.2 Hz, 2×arom. H), 7.19–7.41 (m,
© 2005 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.eurjoc.org Eur. J. Org. Chem. 2005, 3128–31373134
6×arom. H), 7.51 (d, J = 8.2 Hz, 2×arom. H) ppm. 13C NMR: δ
= 18.9 (CH2), 60.2 (CH2), 120.6 (2×arom. CH), 125.7 (1×arom.
CH), 126.0 (2×arom. CH), 127.0 (1×arom. CH), 128.8 (2×arom.
CH), 129.4 (2×arom. CH), 139.8, 149.6 (2×arom. C), 156.9 (C(2)),
180.4 (C=Se) ppm. IR: ν˜ = 1586 (s), 1540 (s), 1486 (m), 1382 (w),
1288 (m), 1249 (w), 1216 (m), 1164 (s), 1152 (m), 1069 (w), 1053
(w), 867 (w), 761 (w), 738 (w), 694 (m) cm–1. CI-MS: 227 (100),
407 (2) [M(78Se) + H]+, 409 (5) [M(80Se) + H]+. C16H15N3Se2
(407.24): C 47.19, H 3.71, N 10.32; found: C 47.05, H 3.59, N
10.08.
Suitable crystals for the X-ray crystal structure determination were
grown from CH2Cl2 by slow evaporation of the solvent.
2-(Phenylimino)-1,3-selenazane-3-carboselenoic Anilide (12): Yield:
345 mg (82%). Orange crystals. M.p. 160–162 °C (CH2Cl2). 1H
NMR: δ = 2.37 (quint, J = 6.8 Hz, CH2), 3.08 (t, J = 6.8 Hz, CH2),
4.42 (t, J = 8.1 Hz, CH2), 6.95 (d, J = 7.3 Hz, 4×arom. H), 7.16
(t, J = 7.4 Hz, 2×arom. H), 7.28–7.37 (m, 4×arom. H) ppm. 13C
NMR: δ = 27.2 (CH2), 28.1 (CH2), 50.7 (CH2), 120.7 (1×arom.
CH), 120.9 (2×arom. CH), 125.1 (2×arom. CH), 129.3 (1×arom.
CH), 129.5 (4×arom. CH), 146.8 (1×arom. C), 149.9 (1×arom.
C), 151.0 (C(2)), 178.2 (C=Se) ppm. IR: ν˜ = 1661 (w), 1606 (s),
1575 (s), 1485 (w), 1420 (w), 1374 (w), 1263 (m), 1239 (w), 1193
(w), 1116 (w), 1023 (w), 902 (w), 844 (w), 762 (s), 694 (s) cm–1. CI-
MS: 240 (68), 420 (45) [M(78Se,78Se) + H]+, 422 (22) [M(78Se,80Se)
+ H]+, 424 (100, [M(80Se,80Se) + H]+. C17H17N3Se2 (421.26): C
48.47, H 4.07, N 9.97; found: C 48.35, H 3.97, N 10.12.
General Procedure for the Preparation of 1,3-Thiazolidines 14 and
1,3-Thiazines 15: A 25 mL round-bottomed flask fitted with a mag-
netic stirrer and condenser was charged with a solution of the ap-
propriate isothiocyanate (1.0 mmol) in CH2Cl2 (20 mL). 2-Bromo-
ethylamine hydrobromide (7) or 3-chloropropylamine hydrochlo-
ride (8; 1.0 mmol) was added, followed by triethylamine (0.28 mL,
2.0 mmol) and the mixture was stirred for 4 h at room temperature.
The mixture was then washed with H2O (3×10 mL) and dried over
MgSO4, and the solvents were evaporated to dryness under reduced
pressure. The crude product was purified by column chromatog-
raphy on silica gel with hexane/AcOEt (1:0 to 1:1).
Phenyl(1,3-thiazolidin-2-yliden)amine (14a): Yield: 173 mg (97%).
White crystals. M.p. 159–161 °C (CH2Cl2). 1H NMR: δ = 3.28 (t,
J = 7.0 Hz, CH2), 3.80 (t, J = 7.0 Hz, CH2), 5.29 (br s, 1 H), 7.03
(t, J = 7.1 Hz, 1×arom. H), 7.12 (d, J = 7.4 Hz, 2×arom. H), 7.28
(t, J = 7.3 Hz, 2×arom. H) ppm. 13C NMR: δ = 31.9 (CH2), 50.7
(CH2), 121.0 (2×arom. CH), 123.1 (1×arom. CH), 128.8
(2×arom. CH), 147.3 (1×arom. C), 161.5 (C(2)) ppm. IR: ν˜ = 1626
(s), 1586 (s), 1490 (m), 1351 (w), 1296 (w), 1204 (m), 1185 (w), 1169
(w), 1154 (w), 1074 (m), 950 (w), 901 (w), 844 (w), 767 (m), 694
(m) cm–1. CI-MS: 179 (100) [M + H]+, 180 (11). C9H10N2S
(178.26): C 60.64, H 5.65, N 15.72; found: C 60.49, H 5.52, N
15.44.
(4-Nitrophenyl)(1,3-thiazolidin-2-yliden)amine (14b): Yield: 219 mg
(98%). White crystals. M.p. 157–159 °C (CH2Cl2). 1H NMR: δ =
3.30 (t, J = 7.0 Hz, CH2), 3.76 (t, J = 7.0 Hz, CH2), 5.40 (br s, 1
H), 6.97, 7.38 (AABB, 4×arom. H) ppm. 13C NMR: 31.5 (CH2),
49.2 (CH2), 122.9 (2×arom. CH), 131.8 (2×arom. CH), 147.3
(1×arom. C), 155.8 (1×arom. C), 161.9 (C(2)) ppm. IR: ν˜ = 1627
(s, br), 1575 (s), 1486 (s), 1459 (m), 1435 (w), 1356 (w), 1301 (w),
1258 (w), 1222 (w), 1206 (m), 1185 (w), 1170 (w), 1101 (w), 1072
(m), 1002 (w), 887 (w), 849 (w), 831 (w), 775 (w) cm–1. CI-MS: 224
(100) [M + H]+, 225 (15). C9H9N3O2S (223.26): C 48.42, H 4.06,
N 18.82, S 14.36; found: C 48.48, H 3.85, N 18.79, S 14.67.
Phenyl(1,3-thiazan-2-yliden)amine (15a): Yield: 190 mg (99%).
White crystals. M.p. 124–125 °C (CH2Cl2). 1H NMR: δ = 1.97–
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2.05 (m, CH2), 2.99 (t, J = 6.0 Hz, CH2), 3.46 (t, J = 5.7 Hz, CH2),
5.47 (br s, 1 H), 7.00 (t, J = 7.2 Hz, 1×arom. H), 7.07 (d, J =
7.3 Hz, 2×arom. H), 7.26 (t, J = 7.4 Hz, 2×arom. H) ppm. 13C
NMR: δ = 22.5 (CH2), 27.0 (CH2), 43.1 (CH2), 122.0 (2×arom.
CH), 122.7 (1×arom. CH), 128.7 (2×arom. CH), 146.1 (1×arom.
C), 151.7 (C(2)) ppm. IR: ν˜ = 1612 (s), 1580 (s), 1492 (s), 1460 (m),
1383 (w), 1347 (w), 1321 (m), 1268 (w), 1217 (m), 1171 (w), 1162
(m), 1102 (w), 1070 (w), 1016 (m), 904 (w), 880 (w), 770 (m), 702
(m) cm–1. CI-MS: 193 (100) [M + H]+, 194 (12). C10H12N2S
(192.28): C 62.46, H 6.29, N 14.57; found: C 62.34, H 6.11, N
14.57.
(4-Nitrophenyl)(1,3-thiazan-2-yliden)amine (15b): Yield: 234 mg
(99%). White crystals. M.p. 156–158 °C (CH2Cl2). 1H NMR: δ =
2.04 (m, CH2), 2.99 (t, J = 6.1 Hz, CH2), 3.44 (t, J = 5.7 Hz, CH2),
5.17 (br s, 1 H), 6.92, 7.35 (AABB, 4×arom. H) ppm. 13C NMR:
22.5 (CH2), 26.9 (CH2), 43.0 (CH2), 123.7 (2×arom. CH), 131.7
(2×arom. CH), 145.4 (1×arom. C), 155.4 (1×arom. C), 162.4
(C(2) ppm. IR: ν˜ = 1624 (s), 1575 (s), 1487 (s), 1463 (m), 1436 (w),
1390 (w), 1352 (w), 1271 (w), 1211 (s), 1171 (w), 1160 (s), 1109 (m),
1064 (w), 1005 (w), 880 (w), 838 (m), 770 (w), 663 (m) cm–1. CI-
MS: 238 (100) [M + H]+, 239 (13). C10H11N3O2S (237.28): C 50.62,
H 4.67, N 17.71, S 13.51; found: C 50.32, H 4.67, N 17.89, S 13.29.
X-ray Crystal Structure Determinations of 9a, 9d, 10a, 10c, and 11
(Figures 1–5):[61] All measurements were performed on a Nonius
KappaCCD area-detector diffractometer[62] with use of graphite-
monochromated Mo-Kα radiation (λ, 0.71073 Å) and an Oxford
Cryosystems Cryostream 700 cooler. The data collection and re-
finement parameters are given below, and views of the molecules
are shown in Figure 1, Figure 2, Figure 3, Figure 4, and Figure 5.
Data reduction was performed with HKL Denzo and Scalepack.[63]
The intensities were corrected for Lorentz and polarization effects,
and absorption corrections based on the multi-scan method[64] were
applied. The structures were solved by direct methods by use of
SIR92,[65] which revealed the positions of all non-H-atoms. In 9a
and 10a, there are two symmetry-independent molecules in the
asymmetric unit. In each case the atomic coordinates of the two
molecules were tested carefully for a relationship from a higher
symmetry space group by use of the PLATON program,[66] but
none could be found. In 9d the methylene groups of the heterocyclic
ring are disordered over two conformations. Two sets of overlap-
ping positions were defined for the atoms of these methylene
groups, and the site occupation factor of the major conformation
was refined to 0.697(8). Similarity restraints were applied to the
chemically equivalent bond lengths and angles involving all disor-
dered C-atoms, while neighboring disordered atoms within and be-
tween each conformation were restrained to have similar atomic
displacement parameters.
For each structure, the non-H-atoms were refined anisotropically.
The amine H-atoms were placed in the positions indicated by a
difference electron density map and their positions were allowed to
refine together with individual isotropic displacement parameters.
All remaining H-atoms were placed in geometrically calculated po-
sitions and refined with the aid of a riding model in which each H-
atom was assigned a fixed isotropic displacement parameter with
a value equal to 1.2 Ueq of its parent C-atom (1.5 Ueq for the methyl
group of 9d). The refinement of each structure was carried out on
F2 by full-matrix, least-squares procedures, which minimized the
function Σw(Fo2 – Fc2)2. A correction for secondary extinction was
applied in all cases. Refinement of the absolute structure parame-
ter[67] for 9a and 11 yielded a value of –0.02(1) in each case, which
confidently confirms that the refined models represent the true ab-
solute structures. In the case of 10a, one reflection, the intensity of
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which was considered to be an extreme outlier, was omitted from
the final refinement. Neutral atom scattering factors for non-H-
atoms were taken from ref.[68], and the scattering factors for H-
atoms were taken from ref.[69] Anomalous dispersion effects were
included in Fc;[70] the values for f and f were those of ref.[71] The
values of the mass attenuation coefficients are those of ref.[72] All
calculations were performed by use of the SHELXL97[73] program.
Crystal Data for 9a: C9H10N2Se,M = 225.09, colorless, prism, crys-
tal dimensions 0.07×0.17×0.22 mm3, monoclinic, space group
P21, Z = 4, a = 10.2191(3) Å, b = 7.4291(2) Å, c = 12.5009(3) Å, β
= 109.531(1)°, V = 894.44(4) Å3, DX = 1.671 g⋅cm–3, μ(Mo-Kα) =
4.138 mm–1, T = 160 K, φ and ω scans, transmission factors (min.;
max.) 0.531; 0.750, 2θmax. = 55°, total reflections measured 19758,
symmetry independent reflections 4011, reflections with I  2σ(I)
3757, reflections used in refinement 4011, parameters refined 226,
restraints 1, R (on F; I  2σ(I) reflections) = 0.0290, wR(F2) (all
reflections) = 0.0692 (w = (σ2(Fo2) + (0.0335P)2 + 0.4923P)–1,
where P = (Fo2 + 2Fc2)/3), goodness of fit 1.047, secondary extinc-
tion coefficient 0.0096(9), final Δmax./σ 0.001, Δρ (max.; min.) =
0.52; –0.50 e·Å–3.
Crystal Data for 9d: C10H12N2OSe, M = 255.12, colorless, tablet,
crystal dimensions 0.07×0.25×0.32 mm3, monoclinic, space group
P21/c, Z = 4, a = 6.2200(1), b = 11.0063(2), c = 15.0659(3) Å, β
= 97.429(1)°, V = 1022.74(3) Å3, DX = 1.657 g⋅cm–3, μ(Mo-Kα) =
3.637 mm–1, T = 160 K, φ and ω scans, transmission factors (min.;
max.) 0.496; 0.785, 2θmax. = 60°, total reflections measured 28650,
symmetry independent reflections 2987, reflections with I  2σ(I)
2557, reflections used in refinement 2987, parameters refined 152,
restraints 39, R (on F; I  2σ(I) reflections) = 0.0274, wR(F2) (all
reflections) = 0.0699 (w = (σ2(Fo2) + (0.037P)2 + 0.3617P)–1, where
P = (Fo2 + 2Fc2)/3), goodness of fit 1.048, secondary extinction
coefficient 0.007(1), final Δmax./σ 0.003, Δρ (max.; min.) = 0.65;
–0.67 e·Å–3.
Crystal Data for 10a: C10H12N2Se, M = 239.12, pale yellow, prism,
crystal dimensions 0.15×0.25×0.25 mm3, monoclinic, space group
P21/n, Z = 8, a = 14.4289(3), b = 10.0607(1), c = 15.1617(3) Å, β
= 114.4143(9)°, V = 2004.14(6) Å3, DX = 1.585 g⋅cm–3, μ(Mo-Kα)
= 3.699 mm–1, T = 160 K, φ and ω scans, transmission factors
(min.; max.) 0.420; 0.585, 2θmax. = 55°, total reflections measured
47957, symmetry independent reflections 4599, reflections with I 
2σ(I) 3914, reflections used in refinement 4598, parameters refined
244, R (on F; I  2σ(I) reflections) = 0.0296, wR(F2) (all reflec-
tions) = 0.0732 (w = (σ2(Fo2) + (0.0341P)2 + 1.3658P)–1, where P
= (Fo2 + 2Fc2)/3), goodness of fit 1.059, secondary extinction coeffi-
cient 0.0031(3), final Δmax./σ 0.001, Δρ (max.; min.) = 0.57; –0.84
e·Å–3.
Crystal Data for 10c: C10H11ClN2Se, M = 273.56, pale yellow,
plate, crystal dimensions 0.05×0.27×0.30 mm3, monoclinic, space
group P21/n, Z = 4, a = 5.8994(1), b = 9.6760(2), c = 19.7407(3) Å,
β = 95.085(1)°, V = 1122.42(3) Å3, DX = 1.619 g⋅cm–3, μ(Mo-Kα)
= 3.543 mm–1, T = 160 K, φ and ω scans, transmission factors
(min.; max.) 0.475; 0.844, 2θmax. = 60°, total reflections measured
28927, symmetry independent reflections 3268, reflections with I 
2σ(I) 2889, reflections used in refinement 3268, parameters refined
132, R (on F; I  2σ(I) reflections) = 0.0293, wR(F2) (all reflec-
tions) = 0.0790 (w = (σ2(Fo2) + (0.0401P)2 + 0.5388P)–1, where P
= (Fo2 + 2Fc2)/3), goodness of fit 1.044, secondary extinction coeffi-
cient 0.007(1), final Δmax./σ 0.002, Δρ (max.; min.) = 0.45; –0.65
e·Å–3.
Crystal Data for 11: C16H15N3Se2, M = 407.11, yellow, prism, crys-
tal dimensions 0.10×0.22×0.25 mm3, monoclinic, space group
P21, Z = 2, a = 6.0296(1), b = 10.4131(3), c = 12.6809(3) Å, β
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= 100.579(2)°, V = 782.66(3) Å3, DX = 1.727 g⋅cm–3, μ(Mo-Kα) =
4.718 mm–1, T = 160 K, φ and ω scans, transmission factors (min.;
max.) 0.302; 0.635, 2θmax. = 60°, total reflections measured 20797,
symmetry independent reflections 4553, reflections with I  2σ(I)
4186, reflections used in refinement 4553, parameters refined 195,
restraints 1, R (on F; I  2σ(I) reflections) = 0.0308, wR(F2) (all
reflections) = 0.0727 (w = (σ2(Fo2) + (0.0359P)2 + 0.3914P)–1,
where P = (Fo2 + 2Fc2)/3), goodness of fit 1.042, secondary extinc-
tion coefficient 0.006(1), final Δmax./σ 0.001, Δρ (max.; min.) =
0.63; –0.78 e·Å–3.
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